Flutiform Treatment in Patients With Asthma in Daily Clinical Practice; a Prospective Observational Non-interventional Study Assessing the Effect of Space Use and Adherence on Fluticasone/Formoterol FDC Efficacy Measured With the Asthma Control Questionnaire (ACQ-6).

Mundipharma Pharmaceuticals B.V.0 个研究点开始时间: 2016年7月最近更新: 2018年11月16日

适应症

试验速览

阶段: 不适用
状态: 撤回
发起方: Mundipharma Pharmaceuticals B.V.
主要终点: Evaluate the effect of frequency of spacer use on asthma control in patients in normal clinical practice

研究概览研究设计入排标准结局指标研究者记录与标识符相似试验

研究概览

简要总结

The objective of the study is to evaluate the effect of frequency of use with a spacer on asthma control in Dutch patients with asthma during their daily clinical practice over 12 weeks treatment.

研究设计

研究类型: Observational
观察模型: Other
时间视角: Prospective

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Patients eligible to be prescribed fluticasone/formoterol fixed dose combination as follows:
•Patients not adequately controlled in inhaled corticosteriods and "as required" inhaled short acting beta 2 agonist or patients already adequately controlled on both an inhaled corticosteriod and a long-acting beta 2 agonist.
•The decision to prescribe fluticasone/formoterol fixed dose combination will precede and be independent of the decision to enroll the patient into the study

排除标准

•There are no specific exclusion criteria as this is an observational study

结局指标

主要结局

Evaluate the effect of frequency of spacer use on asthma control in patients in normal clinical practice

时间窗: This measurement will be taken after 12 weeks of treatment

the Asthma Control Questionnaire will be completed by subjects at study baseline and then after 12 weeks of treatment. Difference between the 2 will be the primary endpoint.

次要结局

未报告次要终点

研究者

发起方

Mundipharma Pharmaceuticals B.V.

申办方类型

Industry

责任方

Sponsor

相似试验

已完成

不适用

A 3-Month Non-Interventional Study of Asthmatics Treatment With Symbicort® Turbuhaler®Asthma

NCT00532922AstraZeneca310

已完成

4 期

The Clinical Effect of Monodisperse Fluticasone Propionate in AsthmaAsthma

NCT01662778Imperial College London21

终止

3 期

Efficacy and Safety of Flutiform K-haler in Patients With Uncontrolled Asthma Following Mid-dose ICS/LABA DPI TherapyAsthma

NCT04124510Mundipharma Korea Ltd20

已完成

4 期

A Study To Investigate The Effect Of Inhaled Fluticasone Propionate On The Bronchial Responsiveness To Leukotriene D4 In Asthmatics PatientsMild AsthmaAsthma

NCT00453778GlaxoSmithKline14

已完成

不适用

Impact of Lung Flute Therapy on AsthmaPersistent Asthma

NCT02003521Medical Acoustics LLC48